Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptor…
$1.18-11.28%
报价 2026-11-13
市值
$118.9M
EV
$157.4M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -77.9%
$0.93$5.35
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CLLSCellectis S.A. | $118.9M | -11.3% | – | 74.7% | – | – | – | |
| PYPDPolyPid Ltd. | $127.2M | -2.2% | – | 0% | – | – | – | |
| CDXSCodexis, Inc. | $127.1M | +21.1% | +10.1% | 79.5% | – | – | – | |
| SPRBSpruce Biosciences, Inc. | $124.5M | +1.0% | +2590.0% | 0% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $124.1M | +1.0% | -18.9% | 99.1% | 29.9x | 8.0x | – | |
| ZURAZura Bio Limited | $119.4M | -13.3% | – | 0% | – | – | – | |
| CUECue Biopharma, Inc. | $117.1M | -7.9% | -84.6% | 99.7% | – | – | – | |
| NERVMinerva Neurosciences, Inc. | $114.6M | -3.4% | -56.2% | 0% | – | – | – | |
| MOLNMolecular Partners AG | $112.7M | -2.3% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -18.9% | 0% | 29.9x | 8.0x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。